9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Estimated reading time: < 1 min

Condition: Pleural Mesothelioma

Estimated Enrollment: 10

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Total number of adverse events for each event reported and the severity and attribution to study therapy of each event,  Percentage of patients with a clinical response to the study treatment,  ,

Interventions: Cyclophosphamide, Fludarabine

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2025

Completion Date: November 2025

Last  Posted Date: February 5, 2019

Location: Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Website Link: https://ClinicalTrials.gov/show/NCT02414945

Was this article helpful?
Dislike 0